Roche Holding AGXSWX:RO -0.29%75 EV-to-EBIT is 16.01 as of Jul. 06, 2026, which is 2% below its 10-year median of 16.30. GuruFocus rates XSWX:RO with a GF Score™ of 75/100 and a GF Value™ of CHF269.24 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 689 Drug Manufacturers companies, Roche Holding AG ranks worse than 50.07% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Roche Holding AG's Enterprise Value for the quarter that ended in Dec. 2025 was CHF288,484 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Roche Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF18,319 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roche Holding AG EV-to-EBIT Related Terms
Roche Holding AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Roche Holding AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Roche Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roche Holding AG EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Roche Holding AG's EV-to-EBIT falls into.
Roche Holding AG's current Enterprise Value is CHF293,378 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Roche Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF18,319 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roche Holding AG (XSWX:RO) has a EV-to-EBIT of 16.01 as of Jul. 06, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Roche Holding AG and its competitors. This is near median its historical median of 16.30. Over the past decade, Roche Holding AG's EV-to-EBIT has ranged from 12.46 to 21.81. According to the industry distribution chart, Roche Holding AG ranks #345 out of 689 companies in the Drug Manufacturers industry, placing it in the top 50.1%.
Is Roche Holding AG's EV-to-EBIT too high?
Roche Holding AG's current EV-to-EBIT of 16.01 is near median its 10-year median of 16.30. Over the past 10 years, this metric has ranged from a low of 12.46 to a high of 21.81. The Drug Manufacturers industry median EV-to-EBIT is 16.01. Roche Holding AG's value of 16.01 is 0% at this industry median. Based on the distribution chart, Roche Holding AG ranks #345 out of 689 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Roche Holding AG has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's EV-to-EBIT compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Roche Holding AG ranks #345 out of 689 companies for EV-to-EBIT. This places Roche Holding AG in the lower half of its industry. The industry median EV-to-EBIT is 16.01. Roche Holding AG's value of 16.01 is 0% at this benchmark. Historically, Roche Holding AG's own EV-to-EBIT has ranged from 12.46 to 21.81 over the past decade. While the company's 10-year median is 16.30 vs. the industry median of 16.01, Roche Holding AG has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.01, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roche Holding AG's current EV-to-EBIT of 16.01 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Roche Holding AG and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roche Holding AG's current EV-to-EBIT is 16.01, which is near median its own 10-year median of 16.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:RO) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF269.24, compared to a current price of CHF346.20 — trading 28.6% above its estimated fair value. The current EV-to-EBIT is 16.01, which is near median its 10-year median of 16.30 and 0% at the Drug Manufacturers industry median of 16.01. Roche Holding AG's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Roche Holding AG (XSWX:RO), the current EV-to-EBIT is 16.01 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roche Holding AG (XSWX:RO) Overvalued in 2026?
Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued.
The current stock price of CHF346.20 is trading 28.6% above its estimated GF Value™ of CHF269.24.
GuruFocus considers Roche Holding AG to be Modestly Overvalued.
Key valuation signals for XSWX:RO:
EV-to-EBIT: 16.01 (near median its 10-year median of 16.30)
GF Value™: CHF269.24 vs. price of CHF346.20 (28.6% above fair value)
Industry Position: 0% at the Drug Manufacturers median (#345 of 689)
No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
75GF Score
Get the complete analysis for XSWX:RO
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RO has been successfully added to your 
